摘要
目的探讨嵌合抗原受体T细胞(Chimeric Antigen Receptor T-Cell,CAR-T)治疗中细胞因子释放综合征(Cytokine Release Syndrome,CRS)的发生机制、分级及管理策略,以促进更安全、有效的CAR-T疗法发展。方法通过对现有研究进行综述,分析CRS的发病机制,包括关键细胞因子及信号通路的参与,并总结CRS的分级标准及临床管理方法。结果CRS是CAR-T治疗的常见不良反应,其发生涉及多种细胞因子(如IL-6、IL-1、IFN-γ等)及信号通路(如JAK/STAT、NF-κB等)的激活。目前已有分级系统指导临床干预,但针对CRS的靶向治疗仍需进一步优化。结论深入理解CRS的机制有助于研发新型靶向药物,从而提升CAR-T治疗的安全性及疗效,为未来研究提供参考。
Objective To investigate the mechanisms,grading,and management strategies of cytokine release syndrome(CRS)in chimeric antigen receptor T-cell(CAR-T)therapy in order to enhance the safety and efficacy of CAR-T cell therapy.Methods By reviewing studies currently available,the pathogenesis of CRS was analyzed,involving the key cytokines and signaling pathways before the grading criteria for and clinical approaches to CRS were summarized.Results CRS,a common adverse reaction in CAR-T therapy,involved the activation of cytokines(e.g.,IL-6,IL-1,IFN-γ)and signaling pathways(e.g.,JAK-STAT,NF-κB).Grading systems that guided clinical interventions were available,but targeted therapies required more optimization.Conclusion A better understanding of CRS mechanisms will facilitate the development of novel targeted drugs while improving the safety/efficacy of CAR-T therapy.
作者
任禹珂
姜华
李路路
李双星
霍桂桃
杨艳伟
张頔
黄瑛
耿兴超
林志
屈哲
REN Yuke;JIANG Hua;LI Lulu;LI Shuangxing;HUO Guitao;YANG Yanwei;ZHANG Di;HUANG Ying;GENG Xingchao;LIN Zhi;QU Zhe(National Institutes for Food and Drug Control,National Center for Safety Evaluation of Drugs,State Key Laboratory of Drug Regulatory Science,Beijing Key Laboratory,Beijing Key Laboratory of Quality Control and Non-clinical Research and Evaluation for Cellular and Gene Therapy Medicinal Products,Beijing 100176,China;National Institutes for Food and Drug Control,Institute for Biological Product Control,Beijing 102629,China)
出处
《中国药物警戒》
2025年第7期735-741,共7页
Chinese Journal of Pharmacovigilance
基金
国家重点研发计划(2024YFA1107302)。
